Elucida Oncology

Nanoparticle Technology - Cancer Applications

Also Clin0 pediatric AML; ELU002 Clin0 brain metastases; ELU003 RD hematological malignancies; ELU004 RD solid tumors; ELU005 RD hematological malignancies

Elucida Oncology is developing targeted cancer therapies for patients with solid tumors and metastatic cancer. To effectively target and kill cancerous cells, Elucida has developed ultra-small nanoparticle C’Dot drug conjugates (CDCs). CDCs are designed to penetrate into tumors and deliver a toxic payload to cancer cells with a much higher payload than antibody-drug conjugates. Using their ultra-small nanoparticle C’Dot drug conjugate (CDC) platform, Elucida is enhancing their therapies to have greater avidity for the target antigen, longer retention in tumors and shortened systemic exposure due to rapid renal clearance. Elucida is developing a pipeline of CDC therapies, with their lead candidate ELU001 currently being tested in Phase 1 clinical trials for various solid tumor indications.

Jobs: